MC38-hCLDN 18.2
品系基本信息
*使用本品系發(fā)表的文獻需注明: MC38-hCLDN 18.2 cell line (Cat. NO. NM-S13-TM10) was purchased from Shanghai Model Organisms Center, Inc..
驗證數(shù)據(jù)
Figure 1. hCLAUDIN18.2 expression in MC38-hCLAUDIN18.2 cell line.
Figure 2. Tumor growth curve of MC38-hCLAUDIN18.2 allogeneic model (n=4).
Figure 3. Body weight curve of MC38-hCLAUDIN18.2 allogeneic model (n=4).
Figure 4. The expression of hCLAUDIN18.2 in humanized modified tumors by FACS.
Figure 5. PD-1 humanized mouse model implanted with MC38-hCLDN18.2 tumors to evaluate the in vivo antitumor efficacy of anti-hCLDN18.2 mAb alone and in combination with Keytruda.
你也可能感興趣
Tamoxifen誘導Cre-ERT2小鼠 使用指南
Cre-ERT2在無Tamoxifen誘導的情況下，在細胞質(zhì)內(nèi)處于無活性狀態(tài)；當Tamoxifen誘導后，Tamoxifen的代謝產(chǎn)物4-OHT（雌激素類似物）與ERT結(jié)合，可使Cre-ERT2進核發(fā)揮Cre重組酶活性。
查看
